2024 | Cellworks

Read more about Biosimulation coupled with personalized tumor microenvironment (TME) modeling predicts response to immunotherapy treatment in NSCLC patients

Read more about Use of biosimulation to predict homologous recombination deficiency and PARPi benefit in patients with ovarian, pancreatic, prostate and triple negative breast cancers

Read more about Integration of genomic aberrations to predict clinical outcomes for patients with gastroesophageal adenocarcinoma receiving neoadjuvant chemotherapy

Subscribe to 2024

Top